USPTO Examiner GODDARD LAURA B - Art Unit 1642

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
18426324PE-STOP Gene Editing System and Gene Knockout Method and ApplicationJanuary 2024April 2025Abandon1521YesNo
18529537MYCOVIRUS-INDUCED GENE SILENCING VECTOR, CONSTRUCTION METHOD AND APPLICATION THEREOFDecember 2023August 2024Allow810NoNo
18500831COMBINATION THERAPY USING AN ANTI-FUCOSYL-GM1 ANTIBODY AND AN ANTI-CD137 ANTIBODYNovember 2023November 2025Abandon2410NoNo
18493604BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENTOctober 2023August 2025Abandon2210NoNo
18478808CHIMERIC PROTEINS AND METHODS OF REGULATING GENE EXPRESSIONSeptember 2023February 2026Allow2800NoNo
18342331COMBINATION THERAPIES FOR TREATING CANCERJune 2023September 2025Abandon2710NoNo
18332076HLA-RESTRICTED VCX/Y PEPTIDES AND T CELL RECEPTORS AND USE THEREOFJune 2023January 2026Abandon3110NoNo
18141363METHODS OF MODIFYING A TARGET POLYNUCLEOTIDE UTILIZING TYPE V CRISPR NUCLEASE POLYPEPTIDES FUSED TO MULTIPLE NUCLEAR LOCALIZATION SIGNALSApril 2023November 2025Abandon3141NoNo
18306562A BISPECIFIC ANTAGONIST COMPRISING A LAG-3 BINDING DOMAINApril 2023June 2025Allow2510NoNo
18137113DISEASE PATHWAY-BASED METHOD TO GENERATE BIOMARKER PANELS TAILORED TO SPECIFIC THERAPEUTICS FOR INDIVIDUALIZED TREATMENTSApril 2023August 2025Abandon2811NoNo
18300825TREATMENT OF METASTATIC BREAST CANCERApril 2023May 2025Abandon2610NoNo
18188098Chimeric and Humanized Anti-Human CTLA4 Monoclonal Antibodies and Uses ThereofMarch 2023July 2025Allow2810NoNo
18183467TREATMENT WITH ANTI-VEGF ANTIBODIESMarch 2023December 2024Abandon2101NoNo
18183107TRISPECIFIC BINDING PROTEINS, METHODS, AND USES THEREOFMarch 2023April 2024Allow1310NoNo
18179289METHOD FOR TREATING CANCER USING ARTIFICIAL ADJUVANT CELL (aAVC)March 2023July 2025Abandon2901NoNo
18169205ANTI-PAD4 AUTOANTIBODIES AS CLINICAL RESPONSE BIOMARKERS FOR THE TREATMENT OF RHEUMATOID ARTHRITISFebruary 2023May 2025Abandon2710NoNo
18161656ANTIBODY BASED GENE THERAPY WITH TISSUE-DIRECTED EXPRESSIONJanuary 2023June 2025Abandon2801NoNo
18161163SINGLE DOMAIN ANTIBODIES TARGETING CD1DJanuary 2023June 2024Allow1600NoNo
18018241ANTI-CD79B ANTIBODY-DRUG CONJUGATE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOFJanuary 2023February 2026Allow3610NoNo
18154380COMBINATION THERAPIES COMPRISING AN AGENT THAT BLOCKS THE INTERACTION BETWEEN CD47 AND SIRPa FOR TREATING GASTRIC OR GASTROESOPHAGEAL JUNCTION CANCERJanuary 2023October 2025Allow3320NoNo
18149972ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCERJanuary 2023December 2024Abandon2410NoNo
18003996ANTI-B7H3 ANTIBODY AND USE THEREOFDecember 2022January 2026Allow3610NoNo
18067669ANTI-CTLA4 AND ANTI-PD-1 BIFUNCTIONAL ANTIBODY, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOFDecember 2022July 2025Allow3120NoNo
18064070CELL SECRETED MINIBODIES AND USES THEREOFDecember 2022February 2026Allow3821NoNo
18058194WNT SIGNALING AGONIST MOLECULESNovember 2022December 2024Abandon2501NoNo
18057949KERATINS AS BIOMARKERS FOR CERVICAL CANCER AND SURVIVALNovember 2022January 2026Abandon3831NoNo
18057165CARRIER-PD-L1 BINDING AGENT COMPOSITIONS FOR TREATING CANCERSNovember 2022August 2025Abandon3320NoNo
17924371VACCINE AGAINST SARS-COV VIRUSNovember 2022February 2026Abandon3900NoNo
18053878CHECKPOINT REGULATOR ANTAGONISTSNovember 2022April 2025Allow2910NoNo
17998240METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSENovember 2022March 2026Abandon4001NoNo
18051551KERATIN 17 AS A BIOMARKER FOR HEAD AND NECK CANCERSNovember 2022December 2025Abandon3720NoNo
17975887CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPYOctober 2022September 2025Abandon3511NoNo
18049793MONOCLONAL ANTIBODIES AGAINST HER2 EPITOPE AND METHODS OF USE THEREOFOctober 2022March 2025Abandon2910NoNo
17996209ANTIBODIES AGAINST SARS-COV-2 AND METHODS OF USING THE SAMEOctober 2022January 2026Abandon3901NoNo
17938492ANTIGEN BINDING PROTEINS, COMPOSITIONS, AND METHODS OF USING THEREOFOctober 2022December 2023Abandon1410NoNo
17938270AGGF1 IMMUNOGENIC COMPOSITIONSOctober 2022May 2025Allow3130NoNo
17934232PSMA Binding Antibody and Uses ThereofSeptember 2022April 2025Allow3120NoNo
17905662RT-PCR DETECTION METHOD AND KIT FOR NOVEL CORONAVIRUSSeptember 2022November 2025Allow3810NoNo
17901391haNK Cetuximab Combinations And MethodsSeptember 2022November 2025Allow3931YesNo
17802124TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN COMBINATION THERAPYAugust 2022November 2025Allow3910NoNo
17886494Combination Treatment Method with E10A and PD1 Monoclonal Antibody for Tumor and Pharmaceutical ApplicationAugust 2022March 2025Abandon3120NoNo
17798261ANTIBODIES PROTECTIVE AGAINST INFLUENZA BAugust 2022December 2025Abandon4010NoNo
17880558Nant Cancer VaccineAugust 2022February 2026Allow4211NoNo
17876164RESTORATION OF T CELL ACTIVITY VIA THE CD39/CD73 AXISJuly 2022November 2024Abandon2810NoNo
17870726METHODS OF TREATING PD-L1 EXPRESSING CANCERJuly 2022May 2025Abandon3411NoNo
17812933METHODS OF TREATING CANCER WITH ANTI-PD-1 ANTIBODIESJuly 2022June 2025Allow3530NoNo
17864335ANTI-CLAUDIN 18 ANTIBODIES AND METHODS OF USE THEREOFJuly 2022December 2025Abandon4110NoNo
17858710NUCLEOLIN-MEDIATED CANCER DIAGNOSTICS AND THERAPYJuly 2022November 2024Abandon2810NoNo
17855437Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer PatientsJune 2022December 2025Abandon4220NoNo
17851462METHODS OF DIAGNOSIS AND THERAPEUTIC TARGETING OF CLINICALLY INTRACTABLE MALIGNANT TUMORSJune 2022September 2024Abandon2701NoNo
17809098PERTUZUMAB VARIANTS AND EVALUATION THEREOFJune 2022October 2024Allow2711YesNo
17847927TRANSFORMING GROWTH FACTOR-BETA LIGAND TRAPS FOR THE TREATMENT OF DISEASEJune 2022December 2025Abandon4241NoNo
17785590METHODS FOR TREATING CANCER USING A COMBINATION OF A PD-1 ANTAGONIST, AN ILT4 ANTAGONIST, AND CHEMOTHERAPEUTIC AGENTSJune 2022December 2025Abandon4210NoNo
17807065FIXED DOSING OF HER ANTIBODIESJune 2022September 2024Abandon2710NoNo
17784617BI-FUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGF-BetaJune 2022December 2025Abandon4210NoNo
17835418DIAGNOSTIC AND THERAPEUTIC METHODS FOR CANCERJune 2022May 2024Allow2310NoNo
17833383BRACHYURY PROTEIN, NON-POXVIRUS NON-YEAST VECTORS ENCODING BRACHYURY PROTEIN, AND THEIR USEJune 2022June 2025Abandon3621NoNo
17782415BISPECIFIC FUSION PROTEIN FOR TUMOR TREATMENTJune 2022October 2025Allow4110NoNo
17781902METHODS OF IDENTIFYING AGENTS THAT BLOCK MCD28 CLEAVAGE BY MMPSJune 2022December 2025Allow4311NoNo
17826258NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHAMay 2022September 2025Abandon4021NoNo
17777914HUMANIZED 4-1BB MONOCLONAL ANTIBODY AND PHARMACEUTICAL COMPOSITION THEREOFMay 2022September 2025Allow4010NoNo
17744271IDENTIFICATION OF PATIENTS IN NEED OF PD-L1 INHIBITOR COTHERAPYMay 2022March 2025Abandon3411NoNo
17743350COMBINATION THERAPIES FOR TREATING CANCERMay 2022June 2024Allow2511NoNo
17776006METHODS FOR TREATING CANCER WITH AN ANTI-APO B100 ANTIBODYMay 2022November 2025Allow4210NoNo
17772980HUMANIZED ANTI-CA IX ANTIBODIES AND METHODS OF THEIR USEApril 2022December 2025Allow4320NoNo
17729970NUCLEOPHOSMIN PROTEIN (NPM) MUTANTS, CORRESPONDING GENE SEQUENCES AND USES THEREOFApril 2022August 2024Abandon2701NoNo
17728491BISPECIFIC ANTIGEN BINDING CONSTRUCTS TARGETING HER2April 2022September 2024Allow2910NoNo
17769881USE OF SUCCINATE AS BIOMARKER IN DIAGNOSIS AND TREATMENT OF CANCERSApril 2022December 2025Allow4411NoNo
17705960METHOD OF IMPROVING EFFICACY OF MELANOMA TREATMENTMarch 2022November 2025Abandon4431NoNo
17761012NKG2D FUSION PROTEINS AND USES THEREOFMarch 2022October 2025Abandon4310NoNo
17642868TUMOR-TARGETING A56 PROTEIN OR FRAGMENT THEREOF, ANTIBODY BINDING TO A56 PROTEIN, AND USE THEREOFMarch 2022December 2025Allow4511NoNo
17688740COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES INVOLVING CXCL1 FUNCTIONMarch 2022January 2023Allow1020NoNo
17687169In Vitro Method for the Prognosis of Progression of a Cancer and of the Outcome in a Patient and Means for Performing Said MethodMarch 2022October 2025Abandon4321NoNo
17652466DCIS RECURRENCE AND INVASIVE BREAST CANCERFebruary 2022December 2024Allow3411NoNo
17670146THERAPEUTIC COMPOSITION AND METHOD COMBINING MULTIPLEX IMMUNOTHERAPY WITH CANCER VACCINE FOR THE TREATMENT OF CANCERFebruary 2022December 2024Allow3451NoNo
17669177ANTI-PD-L1 COMBINATIONS FOR TREATING TUMORSFebruary 2022July 2025Abandon4221NoNo
17592911METHODS OF AND COMPOSITIONS FOR REDUCING GENE EXPRESSION AND/OR ACTIVITYFebruary 2022August 2024Allow3021NoNo
17587708USE OF BETA-CATENIN AS A BIOMARKER FOR TREATING CANCERS USING ANTI-DKK-1 ANTIBODYJanuary 2022January 2025Allow3620NoNo
17578523DETECTION METHOD FOR CANCER USING RNA BIOMARKERSJanuary 2022August 2022Allow610YesNo
17575568Cytotoxic Particles for Targeting P2X7 ReceptorJanuary 2022June 2024Allow2920NoNo
17568376B7H4-TARGETED ANTIBODY-DRUG CONJUGATES AND METHODS OF USE THEREOFJanuary 2022October 2023Allow2210YesNo
17562727METHODS FOR DNA-DEPENDENT TARGETING OF A CELL PERMEANT ANTIBODYDecember 2021July 2024Abandon3110NoNo
17558906Novel Complex Comprising A Cell Penetrating Peptide, A Cargo And A TLR Peptide Agonist For Treatment Of GlioblastomaDecember 2021April 2025Allow3921NoNo
17557801CARRIER-BINDING AGENT COMPOSITIONS AND METHODS OF MAKING AND USING THE SAMEDecember 2021August 2024Abandon3211NoNo
17620381ANTI-PROTEASE NEXIN-1 CONFORMATIONAL SINGLE DOMAIN ANTIBODIES AND USES THEREOF TO CONTROL BLEEDINGDecember 2021March 2026Allow5121YesNo
17550621COMPOSITIONS AND METHODS FOR TREATMENT OF DISEASES INVOLVING CXCL1 FUNCTIONDecember 2021June 2024Abandon3010NoNo
17618642ANTI-DLL3 CHIMERIC ANTIGEN RECEPTORS AND USES THEREOFDecember 2021May 2025Allow4101NoNo
17549367Immune Tolerant Elastin-Like Peptide Tetramer Guided Nanoparticles And Methods Of UseDecember 2021September 2024Allow3321NoNo
17618349MACROPHAGE SPECIFIC ENGAGER COMPOSITIONS AND METHODS OF USE THEREOFDecember 2021September 2025Abandon4501NoNo
17547748MODULATION OF TUMOR IMMUNITY BY PROTEIN-MEDIATED O2 DELIVERYDecember 2021December 2024Allow3620YesNo
17534774THERAPEUTIC SIRP-ALPHA ANTIBODIESNovember 2021October 2023Abandon2300NoNo
17535313TREATMENT AND PREVENTION OF CANCER USING HER3 ANTIGEN-BINDING MOLECULESNovember 2021March 2026Abandon5240YesNo
17531753TREATING CANCER WITH SIGNAL PEPTIDE-REACTIVE T CELLSNovember 2021July 2024Abandon3221NoNo
17455651Immunocompetence Assessment by Adaptive Immune Receptor Diversity and Clonality CharacterizationNovember 2021June 2024Allow3011NoNo
17610897CANCER TREATMENTNovember 2021July 2025Abandon4501NoNo
17505364GENE THERAPY FOR MESOTHELIOMAOctober 2021March 2024Abandon2911NoNo
17480721METHODS AND COMPOSITIONS FOR CANCER TREATMENT AND TREATMENT SELECTIONSeptember 2021December 2023Abandon2701NoNo
17477525ANTI-PD1 AND ANTI-CTLA4 ANTIBODIESSeptember 2021May 2024Allow3210NoNo
17476650Therapeutic Anti-CD9 AntibodySeptember 2021March 2024Allow3021NoNo
17472552PROGRAMMED DEATH 1 LIGAND 1 (PD-L1) BINDING PROTEINS AND METHODS OF USE THEREOFSeptember 2021January 2024Allow2810NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner GODDARD, LAURA B.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
14
Examiner Affirmed
12
(85.7%)
Examiner Reversed
2
(14.3%)
Reversal Percentile
25.6%
Lower than average

What This Means

With a 14.3% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
151
Allowed After Appeal Filing
13
(8.6%)
Not Allowed After Appeal Filing
138
(91.4%)
Filing Benefit Percentile
12.8%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 8.6% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner GODDARD, LAURA B - Prosecution Strategy Guide

Executive Summary

Examiner GODDARD, LAURA B works in Art Unit 1642 and has examined 1,553 patent applications in our dataset. With an allowance rate of 45.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.

Allowance Patterns

Examiner GODDARD, LAURA B's allowance rate of 45.3% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by GODDARD, LAURA B receive 2.03 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by GODDARD, LAURA B is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +21.7% benefit to allowance rate for applications examined by GODDARD, LAURA B. This interview benefit is in the 67% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 18.7% of applications are subsequently allowed. This success rate is in the 18% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 42.1% of cases where such amendments are filed. This entry rate is in the 64% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 50.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 42% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 79.4% of appeals filed. This is in the 71% percentile among all examiners. Of these withdrawals, 88.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.

Petition Practice

When applicants file petitions regarding this examiner's actions, 76.6% are granted (fully or in part). This grant rate is in the 82% percentile among all examiners. Strategic Note: Petitions are frequently granted regarding this examiner's actions compared to other examiners. Per MPEP § 1002.02(c), various examiner actions are petitionable to the Technology Center Director, including prematureness of final rejection, refusal to enter amendments, and requirement for information. If you believe an examiner action is improper, consider filing a petition.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 7.5% of allowed cases (in the 90% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 6.5% of allowed cases (in the 84% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.